I agree completely. Emotionally, I have to keep myself in check and say “$2-5 would be great!”, but intellectually I know that $2-5 means a major exchange and likely much, much greater appreciation. Because $2-5 would almost certainly come with a cleaned up balance sheet and funding picture, as well as partnerships or licensing deals with major BP players that would bring impartial analyst coverage in the market. Pair that with cancer data, and hedge funds would (will) buy this thing up to forward-looking valuations in a heartbeat.

With an uplist and good cancer data, $33/share with our current O/S is eminently reasonable, in my opinion.